Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder

roche.com

Investor Update

Get the latest updates from Investor Update directly as they happen.

Follow now 353 followers

Latest posts

Last updated 2 days ago

Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation

5 days ago

  Roche will publish its Sales for the 3rd Quarter of 2025 prior...

Reminder: Invitation to Roche’s 3rd Quarter Sales 2025 Presentation

5 days ago

  Roche will publish its Sales for the 3rd Quarter of 2025 prior...

FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis

5 days ago

FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as...

Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

7 days ago

Vamikibart is the first non-steroid targeted therapy designed to address inflammation driving...

CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis

8 days ago

Positive recommendation based on phase II NOBILITY and phase III REGENCY data...

Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025

9 days ago

Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial...

Reminder: Invitation to Roche’s Virtual Ophthalmology Investor Event

11 days ago

We are pleased to invite investors and analysts to participate in our...

Roche’s Elecsys® pTau181 becomes the only FDA-cleared blood test for use in primary care to rule out Alzheimer’s-related amyloid pathology

12 days ago

Rules out Alzheimer’s pathology in early stages to enhance diagnostic pathway efficiencyProvides...

Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types

12 days ago

Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced...